Data / Form D filings / Cadence Neuroscience, Inc.
Cadence Neuroscience, Inc.: Form D filings
Cadence Neuroscience, Inc., a biotechnology company in Sammamish, WA, filed 3 Form D notices with the SEC between 2017 and 2023. The latest, on February 28, 2023, reports $26 million sold of a $26 million offering to 7 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2036 223RD PLACE NE, Sammamish, WA, 98074
- Phone
- (425) 681-6863
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1712390
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 28, 2023 | New notice | $26,029,994 | $26,029,994 | 7 | Feb 21, 2023 | sec.gov | |
| Sep 23, 2019 | New notice | $14,999,997 | $2,999,999 | $11,999,998 | 1 | Sep 9, 2019 | sec.gov |
| Jul 31, 2017 | New notice | Indefinite | $0 | 1 | Jul 14, 2017 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| John Douglas Harris | Director | |
| Kevin Douglas Chu | Director | |
| Kent Leyde | Executive Officer, Director | |
| Gerry Douglas Brunk | Director | |
| Warren Douglas Sheffield | Executive Officer |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of Feb 27, 2023 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Cadence Neuroscience, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.